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Malaria rapid diagnostic tests (RDTs) play a critical role in malaria case management, surveillance and case
investigations. Test performance is largely determined by design and quality characteristics, such as detection
sensitivity, specificity, and thermal stability. However, parasite characteristics such as variable or absent expression
of antigens targeted by RDTs can also affect RDT performance. Plasmodium falciparum parasites lacking the PfHRP2
protein, the most common target antigen for detection of P. falciparum, have been reported in some regions.
Therefore, accurately mapping the presence and prevalence of P. falciparum parasites lacking pfhrp2 would be an
important step so that RDTs targeting alternative antigens, or microscopy, can be preferentially selected for use in
such regions. Herein the available evidence and molecular basis for identifying malaria parasites lacking PfHRP2 is
reviewed, and a set of recommended procedures to apply for future investigations for parasites lacking PfHRP2,
is proposed.Role of malaria rapid diagnostic tests (RDTs)
Malaria remains endemic in 104 countries, representing
a major public health problem in many [1]. While most
countries are aggressively controlling malaria, and some
are progressing towards elimination, much of the success
relies on appropriate malaria case management based on
early diagnosis and prompt treatment with efficacious
anti-malarial drugs [2]. To improve case management the
World Health Organization (WHO) recommends that
parasitological confirmation by microscopy or malaria
rapid diagnostic tests (RDTs) is conducted in all patients
with a suspected diagnosis of malaria prior to commen-
cing treatment [3].
The availability of quality-assured malaria RDTs in
recent years has dramatically increased access to malaria
diagnostics. Malaria RDTs are not only playing an in-
creasing critical role in malaria case management, but
also in malaria surveillance and case investigations in
malaria elimination countries. They are also widely used
in non-endemic settings to diagnose malaria in travellers
returning from the tropics [4].* Correspondence: cunninghamj@who.int
7Global Malaria Programme, World Health Organization, Geneva, Switzerland
Full list of author information is available at the end of the article
© 2014 Cheng et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Diagnostic targets of RDTs
Malaria RDTs are lateral flow devices that use antibodies
to capture and detect parasite proteins by immunochroma-
tography. Currently, over 200 brands of RDTs are commer-
cially available for detecting different Plasmodium spp. [5].
Over the past five years 128 unique RDT products have
been tested in the WHO-Foundation for Innovative New
Diagnostics (FIND) Malaria RDT Evaluation Programme
[6]. One hundred and ten (110) of the 127 RDTs that are
capable of diagnosing Plasmodium falciparum, target an
antigen that is unique to P. falciparum, the histidine-rich
protein 2 (PfHRP2). Many antibodies used to detect
PfHRP2 also detect histidine-rich protein 3 (PfHRP3), a
protein that shares a high degree of similarity in amino
acid sequence with PfHRP2 [7]. Indeed, the monoclonal
antibodies in such tests target an epitope abundant in both
proteins [7]. Generally, PfHRP2-detecting RDTs have bet-
ter sensitivity than non-PfHRP2-detecting RDTs, [6] and
tend to have greater thermal stability [8]. These consider-
ations, combined with the higher number of available
products meeting WHO procurement criteria [9] make
PfHRP2-detecting RDTs a widely used diagnostic tool for
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RDTs detecting P. falciparum alone are suitable for use
in much of Western and sub-Saharan Africa where malaria
cases are predominantly caused by P. falciparum. However,
outside of Africa where P. falciparum co-exists with
Plasmodium vivax and other Plasmodium species, RDTs
that detect both P. falciparum and non-falciparum spp.
are typically selected.
Forty-one of 44 African countries and 49 of 55 coun-
tries of other regions have adopted the WHO policy of
parasitological diagnosis for all age groups in 2011 [1].
This was greatly facilitated by the roll out of quality
assured RDTs. Globally, RDT sales reached a total of 205
million in 2012 (129 million PfHRP2, P. falciparum, only
tests) [1].
Performance of RDTs
The detection sensitivity of quality RDTs is generally simi-
lar to that of quality field microscopy. However, variable
performance has been reported in field use [10]. False
negative RDT results will delay anti-malarial treatment,
potentially endangering life and the patient will be a
source for ongoing malaria transmission.
Possible causes for false negative test results
The major causes of false negative results can be grouped
into five broad categories: poor product design or quality,
unsuitable transport or storage conditions, parasite or op-
erator factors and host parasite density/antigen concentra-
tion [11,12] (Table 1).
Many of the potential causes can be eliminated or mini-
mized by procuring good quality RDTs, by improving
quality control of procured RDTs, and by good training
of end users. However, host and parasite characteristics
could be specific to the region where the RDTs are
deployed and are beyond the realms of quality control and
training. Therefore, false negative results should be ex-
haustively investigated, particularly in relation to parasites
not expressing target antigens or expressing, as of yetTable 1 Possible causes of false negative RDT results
Classification Cause of false ne
Product design or quality
Poor detection se
quantity of antibo
Poor visibility of t
Incorrect instructi
Transport or storage conditions Antibody degrada
Parasite factors
Variation in the am
Parasites lacking t
Operator factors Operator error in
Host parasite density
Very low parasite
Prozone effect (hyunrecognized, antigenic variants. In regards to the poten-
tial contribution of the antigenic variants, Baker et al.
found that despite extensive variations in the number and
arrangement of various repeats encoded by the pfhrp2
genes in parasite populations world-wide (458 isolates
examined), no statistically robust correlation between
gene structure and RDT detection rate for P. falciparum
parasites at 200 parasites per microlitre was identified
[13]. Thus, diversity of PfHRP2 does not appear to be a
major cause of RDT sensitivity variation.
Evidence review for parasites not expressing
PfHRP2 and/or PfHRP3
When a parasite expresses little or no target antigen, a
false negative result will occur. P. falciparum parasites
not expressing PfHRP2 and/or PfHRP3 have been repor-
ted both in laboratory and field isolates. In contrast,
there are no reports of parasites failing to express pLDH
or aldolase, as these targets are essential enzymes for
parasite metabolism and survival.
Laboratory lines
Plasmodium falciparum parasites not expressing PfHRP2
were first reported in culture adapted, cloned laboratory
lines: one originating from Papua New Guinea (FCQ27-
D10) [14] and the other, from Thailand (Dd2) [15]. In
both lines, the failure to express PfHRP2 resulted from a
deletion of part [16] or entire protein encoding gene [15]
due to breakage at chromosome ends (subtelomeric
regions). Subpopulations of parasites deleting parts of
the pfhrp2 gene were also observed in a parasite line
(Palo Alto) when cultured in vitro. These subpopulations
showed different breaking points, which appear to be
random within the exon 2 of pfhrp2 [17].
PfHRP3 was reported missing in a parasite line origin-
ating from Honduras (HB3), again due to chromosomal
breakage at the subtelomeric region, resulting in the
deletion of pfhrp3 [18]. Parasites with pfhrp3 gene were
favoured strongly in a genetic cross between 3D7 andgative RDT result
nsitivity of a RDT product due to poor specificity, affinity, or insufficient
dies used in the RDT
est bands due to high background colour on the test
ons for use
tion due to poor durability to heat or to incorrect transport or storage
ino acid sequence of the epitope targeted by the monoclonal antibody
he target antigens or expressing reduced levels of the target antigens
preparing the RDT, performing the test, or interpreting the result
densities/target antigen concentrations
perparasitemia/antigen overload)
Cheng et al. Malaria Journal 2014, 13:283 Page 3 of 8
http://www.malariajournal.com/content/13/1/283HB3 compared to those without pfhrp3, due to rapid
growth of progeny expressing PfHRP3 [18].
Parasites lacking both pfhrp2 and pfhrp3 genes were
observed in a progeny of a genetic cross between Dd2
and HB3 [15]. This progeny inherited the Dd2 parental
type at the pfhrp2 locus on chromosome 8 and the HB3
parental type at PfHRP3 locus on chromosome 13, thus
causing a deletion of both genes. This parasite clone was
able to grow and multiply in vitro with these deletions.
Interestingly, presence of pfhrp2 was not favoured in
inheritance in the progeny [15].
Field isolates
The first definitive report of P. falciparum parasites lack-
ing PfHRP2 and/or PfHRP3 was published by Gamboa
et al. [19]. This discovery was made as part of the WHO-
FIND Malaria RDT Evaluation Programme in which over
300 field isolates were collected from different geograph-
ical areas and characterized for use in malaria RDT prod-
uct testing at the Centers for Disease Control and
Prevention (CDC), USA, and lot testing at the collecting
laboratories. Amongst nine P. falciparum isolates col-
lected in Iquitos, Peru, in 2007, eight were found to lack
the pfhrp2 and six to lack both the pfhrp2 and pfhrp3
genes when tested by PCR. When tested by ELISA, none
of the eight parasites lacking pfhrp2 had detectable PfHRP,
but all had detectable pLDH [19]. Furthermore, parasites
lacking both pfhrp2 and pfhrp3 returned negative results
on three different brands of good quality RDTs.
DNA sequence analysis of the genes flanking pfhrp2 and
pfhrp3 revealed that the lack of PfHRP2 was due to dele-
tions on chromosome 8 which removed pfhrp2 and up-
stream genes, while the lack of PfHRP3 was mostly due to
deletions on chromosome 13 that removed pfhrp3 and its
flanking genes [19]. Deletions of both genes were charac-
terized in more detail using a whole genome scanning ap-
proach in a different set of P. falciparum isolates also
collected from the Iquitos region [20]. Genome scanning
of 14 Peruvian P. falciparum isolates revealed deletions of
subtelomeric regions in lengths of 20–25 kb containing
several genes including pfhrp2 and pfhrp3 [20]. It should
be noted that a truncation of pfhrp3 exon 1 was also seen
in two isolates causing non expression of PfHRP3 [19].
Although not reported to date in field isolates, a frame
shift in these genes could also cause non-expression of the
protein. Based on these published findings, deletions of
pfhrp2 occur because of chromosomal breakage and re-
join in the subtelomeric regions of chromosome 8. The
breaking point could occur in a broad region, often up-
stream of pfhrp2 or within pfhrp2 (Figure 1).
Prevalence and distribution
After characterization and confirmation of P. falciparum
parasites lacking PfHRP2 and PfHRP3 in Iquitos, Gamboaand colleagues [19] performed a retrospective investiga-
tion of the prevalence of these parasites in the Peruvian
Amazon. 148 P. falciparum samples had been collected
between 2003 and 2007 from various locations, and 41%
and 70% of these samples lacked the pfhrp2 and pfhrp3
genes, respectively, with ≈ 22% of the parasites lacking
both pfhrp2 and pfhrp3 genes [19].
Recently, Akinyi et al. [21] retrospectively investigated
the genetic origins of P. falciparum lacking the pfhrp2
gene in Peru. Surrounding Iquitos 13% of P. falciparum
parasites collected between 1998 and 2001 had deleted
pfhrp2. Prevalence increased to 40.6% in samples collec-
ted from the same area between 2003 and 2005 [19]. This
is in perfect agreement with earlier findings [19]. Interest-
ingly, Akinyi et al. showed that pfhrp2 deletions occurred
in 4 of the 5 genetic lineages in the 1998–2001 population,
and in all 8 lineages in the 2003–2005 population [21].
This suggests that pfhrp2 deletion has occurred multiple
times in the Peruvian P. falciparum population and its
prevalence has increased in recent years.
A significant public health problem
Plasmodium falciparum parasites that lack part or all of
the pfhrp2 gene do not express the PfHRP2 protein and
are, therefore, not detectable by PfHRP2-detecting RDTs.
Although some of these parasites still have a functioning
pfhrp3 gene and produce PfHRP3, the lower abundance
of PfHRP3 and the less sensitive detection of this protein
with anti-PfHRP2 antibodies means that infection with
such parasites may only be detectable by PfHRP2-detect-
ing RDTs at higher parasitaemia (>1,000 parasites/μL)
[22]. Therefore, a high prevalence of P. falciparum para-
sites lacking pfhrp2 gene will cause a high rate of false
negative results in PfHRP2-detecting RDTs. This is
especially true in areas with low malaria transmission
where multi-clone infections are rare, i.e. parasite lacking
PfHRP2 are less likely co-infected with another strain hav-
ing PfHRP2 in the same individual, and parasite densities
are usually low. These false negative results will cause a
major problem for malaria case management.
This effect is demonstrated in a recent study comparing
sensitivities of several PfHRP2- and pLDH-based RDTs
for detecting P. falciparum infections in health centres
around Iquitos [23]. Samples used in this study included
19 (25.7% of the parasite isolates) parasite isolates lacking
the pfhrp2 gene. The sensitivity of 10 products based on
PfHRP2 detection was approximately 70 – 72%, with none
of the products detecting any of the 19 isolates containing
parasites without pfhrp2. In contrast, four pLDH-detect-
ing RDTs detected all 19 of these isolates, giving an aver-
age sensitivity of 97-99% [23]. Clearly, the sensitivity of
PfHRP2-detecting RDTs was compromised in this region
and they are not an appropriate diagnostic tool for
diagnosing P. falciparum infections both there and in
Figure 1 Illustration of chromosome breakage points within and flanking the pfhrp2 gene and re-joining of the chromosome.
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deletions. Instead, quality pLDH-detecting RDTs and
microscopy should be used in this region of Peru, and in
contiguous regions in bordering countries.
Importance of correctly mapping parasites
without pfhrp2
The potential impact of P. falciparum parasites lacking
pfhrp2 on malaria case management and on procure-
ment decisions regarding the type of RDTs is significant,
and as such it is imperative that the presence and preva-
lence of these parasites are accurately documented and
mapped. However, incorrect or unsubstantiated report-
ing of parasites lacking pfhrp2 may unnecessarily trigger
a costly change of RDT product (although there is no
guideline as to what prevalence level should trigger this
change), a process which requires significant logistic and
financial support, as well as user retraining. It may also
damage overall user confidence in RDTs. So far, the
rarity of reports summarized in Table 2 suggests pfhrp2
deletion is not a major problem across broad areas; how-
ever, no systematic mapping has occurred. Not to be
underestimated is the difficulty of determining the cause
of false negative RDT results in the field, or when para-
site antigen deletion may be suspected but there is poor
capacity to investigate, and lack of guidance on how to
conduct the investigation. The latter is addressed in the
following sections.Evidence required to document pfhrp2 deletion
Due to the potential consequences of pfhrp2 deletion on
malaria diagnosis at the clinical, public health and
economic levels it is imperative that procedures and
standards are developed in order to confirm new geo-
graphic foci of pfhrp2-deleted parasites. As a minimum,
the following should be collected when reporting or docu-
menting the presence of PfHRP2 deletions.
1. Initial evidence
 The sample is confirmed as microscopy positive
for P. falciparum, the parasitaemia is counted
and all findings are verified by two qualified
microscopists and slide archived. The same
sample does not produce a positive Pf band on
two quality-assured PfHRP2-detecting RDTs
taken from the same box of RDTs that produced
positive results using a positive control, such as a
known RDT positive blood sample. This sample
should also be positive for the pan band if the RDT
detects Pf and pan Plasmodium spp, and positive as
Pf when a pLDH-detecting RDT meeting WHO
procurement criteria is used. The requirement for
a positive pan-band is because pan-bands are
generally less sensitive than HRP2-test bands and
therefore a positive pan-band, and negative HRP2
test band makes the possibility of a false negative
due to low parasite density less probable.
Table 2 Published studies reporting P. falciparum with deletions or no deletions of the pfhrp2 gene
Origin Source
of samples*
Initial evidence Gene deletion analysis by PCR Antigen analysis Ref Prevalence
(no. of samples.
year of collection)
Region Country Area Microscopy Quality
RDT
Species
PCR
pfhrp2
(exon 1 & 2)
No. single
copy genes
Flanking
genes
HRP
ELISA
2nd
quality RDT
South
America
Peru
Iquitos Condorcanqui
Jaen San Lorenzo
Yurimaguas
S D D D D 3 D D D [19] 41% (148, 2003–2007)
D ND D D 3 ND ND ND
Iquitos surrounding S D D D D ND ND D D [23] 25.7% (74, 2010–2011)
Iquitos Padre cocha
Caballococha
Bellavista
U ND ND D D ND D ND ND [21] 20.7% (92, 1998–2001)
40.6% (96, 2003–2005)
Brazil Brazilian Amazon S D D D D ND ND ND ND [24] Case report
French Guiana S D D D D ND ND ND ND [25] 0% (140, 2009–2011)
Africa
Mali Bamako A/S D ND D D 1 ND ND ND [26] 2% (480, 1996)
DRC Gambia Kenya
Mozambique Rwanda
Tanzania Uganda
S D ND D Exon 2 only ND ND D ND [27] 0% (77, 2–19 per country,
2005–2010)
Senegal Dakar S D ND D D 1 ND ND ND [28] 2.4% (136, 2009–2012)
Asia India Chhattisgarh S D D D D 3 D ND D [29] 4.2% (48, 2010)
*Source of samples: S = Symptomatic case, A = Asymptomatic case, U = not specified. D = done; ND = not done.
Note: Quality RDT indicates RDTs meet the WHO RDT recommended procurement criteria based on WHO Malaria RDT Product Testing.
C
heng
et
al.M
alaria
Journal2014,13:283
Page
5
of
8
http://w
w
w
.m
alariajournal.com
/content/13/1/283
Ta
Ge
Cheng et al. Malaria Journal 2014, 13:283 Page 6 of 8
http://www.malariajournal.com/content/13/1/283 The sample is confirmed as P. falciparum by PCR
and ideally quantified against the WHO
International P. falciparum DNA standard [30]
and the sample is negative for other Plasmodium
species by PCR.
If all of the above initial evidence is observed, a
confirmatory investigation should be undertaken. A
blood sample (>50 μL) should be stored frozen or
dried on filter papers (e.g. Whatman 3MM) or other
collection cards as sources of DNA for confirmatory
analyses outlined below. Blood slides and used RDTs
could also be stored as sources of DNA.
2. Confirmatory evidence
 Gene deletion analysisble 3
ne na
Pf3D
Pfh
Pf3D
Pfhr
Pf3D
(M
Pf3D
(Ma. PCR to amplify the full length of exon 2 and
the region across exon 1 and exon 2 of the
gene (See Table 3 for suggested primer
sequences), and fails to amplify a product in at
least one experiment. This is designed to
detect both entire and partial gene deletions
based on known chromosome breaking points,
See Figure 1 (many in exon 2).
b. PCR is able to amplify products for at least
two single copy genes from the same sample.
It does not matter on which chromosome
these genes are located as the purpose is to
verify the quality of DNA in the sample. While
a PCR based on amplification of the 18sRNA
gene is useful in confirming Plasmodium
species, alone it does not provide sufficient
evidence of DNA quality as it is a multi-copy
gene, while pfhrp2 is a single copy gene and,
therefore, more susceptible to false negative
test at low DNA concentration.
c. PCR targeting genes flanking pfhrp2 amplifies
none or only one of the flanking genes
(Table 3 has suggested primers). Deletions
of pfhrp2 often include one or both of the
genes flanking pfhrp2.Suggested primer sequences, PCR conditions and expe
me (previous ID) Primer sequence
7_0831800 5′CAA AAG GAC TTA ATT TAA ATA AGA G3
rp2 exon 2 5′ AAT AAA TTT AAT GGC GTA GGC A3′(rev
5′ ATT ATT ACA CGA AAC TCA AGC AC3′(n
7_0831800 5′ TAT CCG CTG CCG TTT TTG CC 3′
p2 exon 1-2 5′ AGC ATG ATG GGC ATC ATC CTA 3′
7_0831700 5′ AGA CAA GCT ACC AAA GAT GCA GGT G
AL7P1_228) 5′ TAA ATG TGT ATC TCC TGA GGT AGC 3′
7_0831900 5′ TAT GAA CGC AAT TTA AGT GAG GCA G
AL7P1_230) 5′ TAT CCA ATC CTT CCT TTG CAA CAC C 3 Antigen analysis
a. To confirm that the parasite lacks the
pfHRP2 protein, a second brand of quality
PfHRP2-detecting RDT should be used to test
the sample, and again a negative result should
be produced. Ideally, this second RDT would
use different antibodies, but this information is
frequently not available.
b. Alternatively, a PfHRP2 ELISA could be
performed, and again yield a negative result at
a parasitaemia where the ELISA would be
expected to be positive. A PfHRP2 variant with
poor affinity for the antibodies used in the
ELISA is conceivable but highly unlikely to
occur and therefore, this step provides the
most definitive proof of lack of functional
protein due to partial or entire gene deletion.
It should be noted that antigen analysis is also
important for reporting no pfhrp2 deletions
because a frame shift within pfhrp2 will also
lead to a false negative RDT result, even if the
gene is present.
3. Establish prevalence
Following confirmation of pfhrp2 deletions in initial
case investigations, surveillance of fever patients or
community surveys around index cases should be
carried out in the specific geographic region to
determine the prevalence of parasites carrying gene
deletions. Retrospective studies are an option if
stored samples from the same region are available.
Outside Peru, prevalence of parasites lacking pfhrp2
is almost certainly extremely low, but foci of deleted
parasites may exist – the Peruvian deleted
population went unrecognized until sample
collection was undertaken for purposes other than
case management. In such cases, a large number of
samples may be required to establish reliable
estimates of the prevalence of these parasites. In all
cases, prevalence estimates should be accompaniedcted product sizes [19,22]
Annealing Tm Expected product size
′(forward) 55°C 600 -1000 bp
erse)
ested forward)
57°C 303 bp
3′ 60°C 227 bp
3′ 68°C 346 bp
′
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put in place for clinicians to collect appropriate
samples when suspicious false negative cases arise,
including frozen and dry blood spots samples,Summary of studies reporting pfhrp2 deletions or
no deletions
Since the first report of P. falciparum parasites lacking
pfhrp2 gene in 2010 [19], several publications have re-
ported detection of these parasites in Peru and other areas
[21,23,24,26,28,29]. The approaches used in these studies
have varied. In Table 2, these studies are summarized
against the recommended procedures outlined. The ma-
jority of studies meet most of the ‘initial evidence’ criteria,
however, few follow up confirmatory tests are reported,
including the quality of DNA, the deletion of flanking
genes and antigen analysis.
Conclusions
After reviewing published data we believe that unequivo-
cal evidence exists for pfhrp2 and pfhrp3 gene deletions in
P. falciparum in Peruvian Amazon at a high prevalence
(40.6% in Iquitos and 2-40% in surrounding areas) [19,23].
Therefore, PfHRP2-detecting RDTs should not be used in
this area of South America as a basis for treatment
decisions. It is important that vigilance is high in other
parts of Peru and of South America generally in order to
determine the geographic spread of parasites with gene
deletions.
In areas outside of South America, further studies
should be undertaken to verify the existence, and if
present, the prevalence and geographical extent of popu-
lations of parasites with gene deletions. Overwhelmingly,
operational experience on RDT use indicates that there
is no reason why PfHRP2-detecting RDTs should not be
used as part of routine clinical case management in most
malaria-endemic areas, they are safe and effective for case
management [31-35]. Investigations should be carried out
in cases where discrepant results are seen between differ-
ent diagnostic methods that are not due to low parasite
density in samples.
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